BridgeBio Pharma (BBIO)
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Electrification of the Iepuresti project in Romania has been completed and gradual power supply to the grid has begun, continuation
Clinical trial NCT05375162: enrollment: not set → 304 participants.
Clinical trial NCT07293351: enrollment: not set → 254 participants.
Clinical trial NCT05637112: enrollment: not set → 551 participants.
Clinical trial NCT07477509: enrollment: not set → 2500 participants.
Clinical trial NCT06843447: enrollment: not set → 460 participants.
Clinical trial NCT06966492: enrollment: not set → 20 participants.